Get informed when a big investor buys or sells
+ Follow627.41
The PEG ratio measures a stock's valuation relative to its earnings growth rate. A PEG ratio below 1.0 may indicate that the stock is undervalued relative to its growth potential.
Steminent Biotherapeutics (7729.TWO) currently reports a PEG ratio of 627.41. That is above the Healthcare sector average of -6.46. Use the charts on this page to explore Steminent Biotherapeutics's PEG ratio history and peer comparisons.
Steminent Biotherapeutics's PEG ratio of 627.41 is higher than the Healthcare sector average of -6.46. That is roughly 9809.3% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
The PEG ratio is a valuation multiple that relates Steminent Biotherapeutics's market price to a fundamental measure such as earnings, sales, or book value. At 627.41, 7729.TWO can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.
Start with the current PEG ratio of 627.41, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is -6.46. From there, open related valuation or income-statement pages for Steminent Biotherapeutics, and consider following 7729.TWO for alerts when major investors trade the stock.
Steminent Biotherapeutics is classified in the Healthcare sector. On PEG ratio, it currently shows 627.41 versus a sector average near -6.46. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing 7729.TWO with unrelated industries.